Jump to content

FV-100: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
Citation bot (talk | contribs)
Bots
5,429,602 edits
Added work. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar
 
(9 intermediate revisions by 7 users not shown)
Line 4: Line 4:
| ImageFile=Cf1743.png
| ImageFile=Cf1743.png
| ImageSize=200px
| ImageSize=200px
| IUPACName=3-[(2''R'',4''S'',5''R'')-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2-one
| IUPACName=3-(2-Deoxy-β-<small>D</small>-''erythro''-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-''d'']pyrimidin-2(3''H'')-one
| SystematicName=3-[(2''R'',4''S'',5''R'')-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-''d'']pyrimidin-2(3''H'')-one
| OtherNames=Cf1743
| OtherNames=Cf1743
|Section1={{Chembox Identifiers
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|changed|FDA}}
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo= 956483-02-6
⚫
| UNII = 0NJ5F6D4U7
| ChEMBL = 344738
| CASNo=
| ChemSpiderID = 431897
| PubChem=493485
| PubChem=493485
| UNII_Ref = {{fdacite|correct|FDA}}
⚫
| UNII = 0NJ5F6D4U7
| StdInChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
| StdInChIKey = MFGSDSRTGUVZQG-DFQSSKMNSA-N
| SMILES=CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O
| SMILES=CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O
}}
}}
Line 28: Line 34:
}}
}}


'''FV-100''', also known as '''Cf1743''', is an orally available [[nucleoside analogue]] drug<ref>{{citation |url=http://www.medicalnewstoday.com/articles/138537.php |title=Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies |year=2009 }}</ref> with [[antiviral medicine|antiviral]] activity.<ref>{{cite journal | doi = 10.1093/jac/dkp294 |author1=McGuigan, Christopher |author2=Balzarini, Jan | title = FV100 as a new approach for the possible treatment of varicella-zoster virus infection | journal = [[Journal of Antimicrobial Chemotherapy]] | year = 2009 | volume = 64 | issue = 4 | pages = 671–673 | pmid = 19679595}}</ref> It may be effective against [[shingles]].<ref>Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. ''J Med Virol''. 2017 Jul;89(7):1255-1264. {{doi|10.1002/jmv.24750}} {{pmid|27943311}}</ref>
'''FV-100''', also known as '''Cf1743''', is an orally available [[nucleoside analogue]] drug<ref>{{citation |url=http://www.medicalnewstoday.com/articles/138537.php |title=Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies |year=2009 }}</ref> with [[antiviral medicine|antiviral]] activity.<ref>{{cite journal | doi = 10.1093/jac/dkp294 |author1=McGuigan, Christopher |author2=Balzarini, Jan | title = FV100 as a new approach for the possible treatment of varicella-zoster virus infection | journal = [[Journal of Antimicrobial Chemotherapy]] | year = 2009 | volume = 64 | issue = 4 | pages = 671–673 | pmid = 19679595| doi-access = free }}</ref> It may be effective against [[shingles]].<ref>Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. ''J Med Virol''. 2017 Jul;89(7):1255-1264. {{doi|10.1002/jmv.24750}} {{PMID|27943311}}</ref>


It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.<ref>{{citation |url=http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html |title=Step forward for shingles drug - FV100. |author1=Cardiff School of Pharmacy |author2=Pharmaceutical Sciences }} Shows structure of FV100.</ref>
It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.<ref>{{citation |url=http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html |title=Step forward for shingles drug - FV100. |author1=Cardiff School of Pharmacy |author2=Pharmaceutical Sciences }} Shows structure of FV100.</ref>


==Clinical trials==
==Clinical trials==
FV-100 was tested against [[valaciclovir]] in a [[phase II trial]] in patients with [[herpes zoster]]. The trial was sponsored by Bristol-Myers Squibb.<ref>{{citation |url=http://clinicaltrials.gov/ct2/show/NCT00900783 |title=A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster }}</ref> The drug is currently being developed by [http://contravir.com/ ContraVir Pharmaceuticals, Inc.], [[Edison, New Jersey]].<ref>{{citation |url= http://www.dddmag.com/news/2015/01/contravir-pharmaceuticals-fda-meeting-about-antiviral-drug-trial?et_cid=4352306&et_rid=297252576&type=cta| title=ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.| date=January 2015 }}</ref> It has reached Phase III clinical trials.<ref>De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. ''Clin Microbiol Rev''. 2016 Jul;29(3):695-747. {{doi|10.1128/CMR.00102-15}} {{pmid|27281742}}</ref>
FV-100 was tested against [[valaciclovir]] in a [[phase II trial]] in patients with [[herpes zoster]]. The trial was sponsored by Bristol-Myers Squibb.<ref>{{citation |url=http://clinicaltrials.gov/ct2/show/NCT00900783 |title=A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster |date=23 September 2015 }}</ref> The drug is currently being developed by [http://contravir.com/ ContraVir Pharmaceuticals, Inc.], [[Edison, New Jersey]].<ref>{{citation |url= http://www.dddmag.com/news/2015/01/contravir-pharmaceuticals-fda-meeting-about-antiviral-drug-trial?et_cid=4352306&et_rid=297252576&type=cta| title=ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.| work=Drug Discovery & Development| date=January 2015 }}</ref> It has reached Phase III clinical trials.<ref>De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. ''Clin Microbiol Rev''. 2016 Jul;29(3):695-747. {{doi|10.1128/CMR.00102-15}} {{PMID|27281742}}</ref>


==References==
==References==
{{reflist}}
{{reflist}}



{{Antivirals}}
{{Antivirals}}
Line 43: Line 48:
[[Category:Anti-herpes virus drugs]]
[[Category:Anti-herpes virus drugs]]
[[Category:Nucleosides]]
[[Category:Nucleosides]]
[[Category:Antivirals]]
[[Category:Antiviral drugs]]
[[Category:Furopyrimidines]]
[[Category:Furopyrimidines]]
[[Category:Tetrahydrofurans]]
[[Category:Tetrahydrofurans]]

Latest revision as of 11:22, 27 December 2024

FV-100
Names
IUPAC name
3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Systematic IUPAC name
3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Other names
Cf1743
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
    Key: MFGSDSRTGUVZQG-DFQSSKMNSA-N
  • CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O
Properties
C22H26N2O5
Molar mass 398.459 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug[1] with antiviral activity.[2] It may be effective against shingles.[3]

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.[4]

Clinical trials

[edit]

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb.[5] The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey.[6] It has reached Phase III clinical trials.[7]

References

[edit]
  1. ^ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
  2. ^ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
  3. ^ Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. doi:10.1002/jmv.24750 PMID 27943311
  4. ^ Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.
  5. ^ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015
  6. ^ "ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.", Drug Discovery & Development, January 2015
  7. ^ De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi:10.1128/CMR.00102-15 PMID 27281742


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=FV-100&oldid=1265535558"